icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
13 Oct, 2020 01:37

Johnson & Johnson pauses coronavirus vaccine study, citing ‘unexplained illness’ in volunteer

Johnson & Johnson pauses coronavirus vaccine study, citing ‘unexplained illness’ in volunteer

Johnson & Johnson has temporarily halted its coronavirus vaccine trial after a trial participant contracted an “unexplained illness,” the company said, though offered few additional details about the setback.

The pharma firm’s 60,000-patient vaccine study was paused due to an adverse reaction in a volunteer, J&J confirmed to Stat News on Monday, citing privacy concerns while declining to outline the patient’s symptoms.

“We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information,” the company said in a statement.

Also on rt.com Second AstraZeneca volunteer reportedly suffers rare neurological condition, but UK company says it’s not related to vaccine 

While J&J said it had ordered a study pause, it clarified that the FDA has not yet placed the trial on clinical hold, which would entail a longer delay in the testing process.

J&J’s vaccine candidate is not the only one thought to be linked to adverse effects in trial volunteers, as AstraZeneca’s inoculation has also resulted in unexplained symptoms in two participants, at least one of which developed a “rare neurological condition” following her second dose, prompting the company to pause testing for a safety review. Though the second patient’s symptoms have not been disclosed, an unnamed source familiar with the trial told the New York Times they exhibited the same illness as the first, a condition known as transverse myelitis.

Also on rt.com Pfizer expands coronavirus vaccine trial to include children as young as 12

Like this story? Share it with a friend!

Podcasts
0:00
23:13
0:00
25:0